Deuteroncology
Liege, BE · 1 known investors
DeuterOncology is a clinical-stage biotech developing DO-2, a deuterated, brain-penetrant MET kinase and RAS pathway inhibitor for cancer patients, currently in a phase 1 clinical study. The molecule was in-licensed from OCTIMET Oncology and originally from Janssen Pharmaceutica.
Founders & leadership
DT
Dr Timothy Perera
TP
Timothy PereraFounder & CEO